Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Outsourced Pharmaceutical Commercialization Market Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Published September 2024

The investment outlook for outsourced pharmaceutical commercialization remains highly favorable as pharmaceutical companies increasingly seek to optimize a drug product’s market launch and ongoing commercial success. As pharmaceutical companies navigate increasing R&D complexities and a dynamic regulatory environment, leveraging third-party expertise is more critical than ever to optimize operations and accelerate innovation.

  1. Increasingly Complex Drug Pipeline: Specialty drugs have grown from 15% to 44% of pharmacy revenues (2010-2020)
  2. Rising R&D Spend: U.S. pharmaceutical research and development spending has grown at a 7.7% CAGR (2013-2022)
  3. Expanding Outsourced Services Market: The global pharmaceutical outsourcing market is projected to grow at a 5.7% CAGR (2022-2032E)

Provident’s Pharmaceutical Commercialization Coverage Team is pleased to announce the release of its Fall 2024 industry overview, featuring key statistics, emerging trends, competitive landscapes, and transaction considerations. A preview of the presentation is available below. For full access, please contact the Pharmaceutical Commercialization Coverage Team at pharmacommercialization@providenthp.com.

[holo_button icon=”/wp-content/uploads/2024/09/PHP-Pharma-Commercialization-Market-Update-Fall-2024-vSend-Blinded.pdf” link=” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]